Skip to main
IMCR
IMCR logo

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 6%

Bulls say

Immunocore Holdings PLC is positioned favorably due to its strong clinical activity manifestations, particularly regarding the IMC-F106C and its increasing probability of success in various therapeutic areas, including non-small cell lung cancer (NSCLC). The company's flagship product, KIMMTRAK, has demonstrated a substantial survival advantage over existing treatments for metastatic uveal melanoma, leading to solid early sales and quick market adoption. Moreover, anticipated data readouts related to their pipeline products could serve as significant catalysts, further solidifying Immunocore's leadership in TCR-based immunotherapies and enhancing its positive investment outlook.

Bears say

Immunocore Holdings faces a negative outlook primarily due to the bear case assumptions highlighting potential clinical shortcomings, with minimal expected benefit from its PRAME clinical readouts and low projected probabilities of success for therapies targeting various cancers. Additionally, the company's struggle to develop effective therapies against HIV, particularly given the virus's ability to evade immune responses and the complexities involved in treatment safety and scalability, further dampens its future prospects. The reliance on its ImmTAC, ImmTAV, and ImmTAI platforms for generating successful clinical candidates raises concerns about the company’s overall capacity to innovate and achieve sustained growth in its drug pipeline.

Immunocore Holdings (IMCR) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 18 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.